Medicinal chemists — do you know where your drug is (and what it is doing) ?

There are been two interesting posts on other blogs concerning the proposed governmental center for drug discovery — and
Everyone’s for discovering new drugs, the question is how best to do it.  The following is an old post of mine on the Skeptical Chymist (which seems to have disappeared).  Drug discovery, if it is not to be blind luck (a future post will give a few examples of how we backed into some of the most useful drugs we have) should be based on some sort of understanding of how the disorder to be treated came about.  This post shows that even when we think we know how a given drug is working, we really don’t.
Reading the biomedical literature is like reading a large Russian novel with thousands of characters who interact in unexpected ways.A recent paper [ Nature Medicine vol. 14 pp. 382 -391 ’08 ] brings together 3 such actors — CFTR, the protein mutated in cystic fibrosis, ceramide, a molecule only of interest to neurologists until recently, and amitriptyline, a drug for depression whose mechanism of action was (seemingly) known.

Start with CFTR, a huge protein (1480 amino acids).CFTR mutations cause cystic fibrosis, the commonest hereditary disease of Caucasians.There must be some selective advantage to CFTR mutations as over 600 were known as of 2003.However just one accounts for > 50% of all cases. It is a deletion of phenylalanine at position #508 (showing just how delicate protein structure and function really is). One guess is that the mutants protect against intestinal pathogens (infantile diarrhea kills many children in the developing world).

Ceramide and its derivatives contain two saturated unbranched hydrocarbon chains (16 – 20 carbons long).They are found in myelin (the wrapping of nerve fibers) which is mostly lipid.All sorts of awful hereditary neurological diseases (usually affecting children but fortunately rare) are due to accumulation of molecules containing ceramide.In recent years ceramide’s effects on non-neuronal cell proliferation and/or cell death have become prominent.Ceramide is a second messenger.The intracellular effects of ceramide in the normal workings of the brain haven’t been much studied.

Amitriptyline (Elavil) was one of the earliest antidepressants.We all knew how it worked — by blocking the reuptake of neurotransmitters such as serotonin and norepinephrine from the synapse (except that this is an acute effect and this class of drugs (the tricyclic antidepressants) takes a few weeks to work).
Surely you see how all this fits together at this point.No? I didn’t either.Read on.

It turns out that CFTR mutations increase the levels of ceramide inside the lungs (the primary site of infection in cystic fibrosis).This is due to alkalinization of the intracellular sites where ceramide is broken down.Elevated ceramide levels are held to increase cell death resulting in lung infection (the bacteria have more to munch on).

Where does amitriptyline fit in?It lowers lung ceramide levels.How? By decreasing the amount and/or the activity of an enzyme (acid sphingomyelinase) which breaks down a precursor of ceramide.The paper is silent on the mechanism(s) by which this happens (but does give two references #24, #25).

Where does the effect of amitriptyline on neurotransmitter reuptake fit into all of this?It doesn’t, and that’s just the point.

Nowadays, medicinal chemists design organic molecules to fit into slots of proteins whose function they are trying to alter.The tricyclic antidepressants weren’t discovered this way (they are much older), but papers like Mol. Pharmacol. vol. 50 pp. 957 – 965 ’96 found the crucial amino acids in the reuptake protein to which they bind.A fairly open and shut case for their mechanism of action.

Except it isn’t.Who knows how many designer drugs are really working the way we think they do.A cautionary tale.

Post a comment or leave a trackback: Trackback URL.


  • Wavefunction  On February 3, 2011 at 4:14 pm

    Quite true. Just consider nortriptyline vs amitriptyline. The difference of a single methyl group causes a big difference in NT vs 5-HT transporter inhibition selectivity which concomitantly impacts antidepressant action. Also, the mechanism of action of some of these molecules cannot be illuminated simply by looking at direct drug-binding pocket interactions but by looking at the perturbation of the entire physiological pathway that the protein is involved in. We now know that a drug does not just inhibit a protein, it inhibits a process. Understanding how inhibiting the protein selectively modulates components of the entire process is going to be key.

    But there is hope. In case of antidepressants and antipsychotics, probably the most fascinating phenomenon to emerge recently is functional selectivity which I blogged about before. I think functional selectivity holds real promise for unraveling some of the mysteries of antidepressant/antipsychotic-GPCR/transporter interactions you mention.

  • Morten G  On May 18, 2012 at 12:09 pm

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: